Letters to the Editor

Timing Is Everything in Intracerebral Hemorrhage

To the Editor:

Hallevi and coworkers recently reported on the off-label use of rFVIIa in 46 patients with ICH.1 Twenty-four patients received rFVIIa within 3 hours, and 22 within 3 to 4 hours. Volume increase and outcome at discharge were compared with 148 historical controls. The authors did not find a difference in reduction of volume increase between the 0 to 3 and the 3 to 4 hour group. Nor did they find a difference in outcome between the factor VIIa treated and the control patients. They conclude that timing of hemostatic therapy may not have an influence on volume reduction or outcome in ICH patients.

We are not as quick to agree with this conclusion, for the following reasons: First, mean volumes were remarkably smaller—only one-third—than volumes that were found in FAST.2 Size of baseline volume plays an important role because it is a predictor of growth and outcome.3 Growth reductions may have a more important impact on outcome when baseline ICH volume is larger to begin with. Second, volume was measured with the ABC/2 method. This method was developed for assessing volume at bedside. Though the inter-rater agreement for hematoma volume was assessed as “excellent,” this method may still be imprecise. This may be important because, as we have recently shown, every milliliter counts when it comes to the relation of outcome and mortality.4 Third, edema volume was not assessed and IVH volume was only registered as absent or present. It is, however, known that both these variables may have an important impact on outcome. Thus, Gebel and coworkers found better outcomes with higher relative edema volumes.5 Several studies have shown that IVH volume is an independent predictor of poor outcome,6,7,8 and increases in IVH volume within 24 hours was another predictor of poor outcome.8

Hallevi and coworkers reported that 5.4% of the rFVIIa-treated patients had bleeding related to warfarin intake and another 9% had hematoma evacuation. These patients (14%) were removed from the efficacy analysis, which further reduces the already small number of patients, further questioning the meaningfulness of the conclusions.

Concerning safety, the authors report thrombotic events in 12.9% of rFVIIa-treated patients. In the discussion, they refer to the ongoing issue of safety of rFVIIa. It would have been interesting to know whether there were thrombotic events in the control group. This is particularly critical because the discussion about the relation of safety and outcome certainly needs a consideration of controls, given the large differences in outcome between the placebo groups of the Phase-II and the FAST trial.

Finally, with 24 and 22 patients in the 2 treatment groups, the power to say anything about timing of treatment and growth of ICH and outcome is extraordinarily limited—particularly when other baseline variables are strongly related to both outcome and hemorrhage growth and act as confounders. Direct comparisons between the 2 treatment groups on these other key variables would be highly unlikely to be significant without enormous differences, again because of the very small sample size.

We performed an analysis on data from FAST to identify a subgroup of patients who may benefit from treatment.9 This analysis demonstrated that, besides age and baseline volume of ICH and IVH, timing of treatment within 2.5 hours were prerequisite conditions for good clinical outcome with rFVIIa.

We have also demonstrated that rFVIIa decreases hemorrhage growth in both the Phase-II and Phase-III FAST trials,2 and that growth of ICH decreases with increasing time from onset of ICH.3 Thus, there is a relationship between time-to-treatment with rFVIIa and its effect on growth of ICH. What has yet to be demonstrated in a Phase-III trial is that the decrease in hemorrhage growth is associated with improved long-term outcome, and here timing may play a key role.

Disclosures

Dr Skolnick is an employee of Novo Nordisk and stockholder in the company. Dr Mayer has received research support from Novo Nordisk. Drs Mayer, Broderick, Davis, Diringer, and Steiner report receiving consulting fees from Novo Nordisk, and Drs Mayer, Davis, Diringer, and Steiner report receiving lecture fees from Novo Nordisk.

Thorsten Steiner, MD
Department of Neurology
University of Heidelberg
Heidelberg, Germany

Joseph Broderick, MD
Department of Neurology
The Neuroscience Institute
University of Cincinnati Medical Center
Cincinnati, Ohio, USA

Nikolai C. Brun, MD, PhD
Nordic Genzyme A/S
Copenhagen S, Denmark

Stephen M. Davis, MD, FRACP
Department of Neurology
Royal Melbourne Hospital/University of Melbourne
Parkville, Australia

Michael N. Diringer, MD
Neurology/Neurosurgery Intensive Care Unit
Washington University School of Medicine
St Louis, Mo, USA

Stephan Mayer, MD
Departments of Neurology and Neurosurgery
Columbia University College of Physicians and Surgeons
New York, NY, USA

(Stroke. 2008;39:e117-e118.)
© 2008 American Heart Association, Inc.
Stroke is available at http://stroke.ahajournals.org
DOI: 10.1161/STROKEAHA.108.517979
Brett E. Skolnick, PhD
Novo Nordisk Inc
Princeton, NJ, USA


Timing Is Everything in Intracerebral Hemorrhage
Thorsten Steiner, Joseph Broderick, Nikolai C. Brun, Stephen M. Davis, Michael N. Diringer, Stephan Mayer and Brett E. Skolnick

*Stroke*. 2008;39:e117-e118; originally published online May 22, 2008; doi: 10.1161/STROKEAHA.108.517979

*Stroke* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/39/7/e117

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Stroke* is online at:
http://stroke.ahajournals.org/subscriptions/